Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

AFT Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

AFT Pharmaceuticals hat ein Gesamteigenkapital von NZ$73.9M und eine Gesamtverschuldung von NZ$36.8M, wodurch sich der Verschuldungsgrad auf 49.8% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen NZ$158.9M bzw. NZ$85.0M. AFT Pharmaceuticals Das EBIT des Unternehmens beträgt NZ$19.5M, so dass der Zinsdeckungsgrad 6 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von NZ$6.2M.

Wichtige Informationen

32.1%

Verhältnis von Schulden zu Eigenkapital

NZ$28.20m

Verschuldung

Zinsdeckungsgrad	6.6x
Bargeld	NZ$12.04m
Eigenkapital	NZ$87.80m
Gesamtverbindlichkeiten	NZ$77.46m
Gesamtvermögen	NZ$165.26m

Jüngste Berichte zur Finanzlage

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Jan 02

Recent updates

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

Jul 30

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Jun 02

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

Mar 20

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Feb 13

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Jan 23

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Jan 02

Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

Dec 12

AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 21

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: AFTDie kurzfristigen Aktiva des Unternehmens (NZ$95.1M) übersteigen seine kurzfristigen Passiva (NZ$48.3M).

Langfristige Verbindlichkeiten: AFTDie kurzfristigen Vermögenswerte des Unternehmens (NZ$95.1M) übersteigen seine langfristigen Verbindlichkeiten (NZ$36.6M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: AFTDie Nettoverschuldung im Verhältnis zum Eigenkapital (18.4%) wird als zufriedenstellend angesehen.

Schulden abbauen: AFT Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 1416.8% auf 49.8% zurückgegangen.

Schuldendeckung: AFTDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (35.7%).

Zinsdeckung: Die Zinszahlungen für die Schulden von AFT sind durch das EBIT gut gedeckt (6x coverage).

AFT Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Recent updates

Full year 2024 earnings released: EPS: NZ$0.15 (vs NZ$0.10 in FY 2023)

AFT Pharmaceuticals Limited to Report Fiscal Year 2024 Results on May 23, 2024

Price target decreased by 22% to NZ$3.70

Consensus EPS estimates fall by 12%, revenue upgraded

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2024

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited to Report First Half, 2024 Results on Nov 23, 2023

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Announces Board Changes

Independent Non-Executive Director recently sold NZ$109k worth of stock

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023

Consensus EPS estimates fall by 17%

Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year Ending March 2024

AFT Pharmaceuticals Limited to Report Fiscal Year 2023 Results on May 22, 2023

Price target decreased to NZ$4.22

Consensus forecasts updated

First half 2023 earnings released: EPS: NZ$0.01 (vs NZ$0.04 in 1H 2022)

Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?

Price target decreased to NZ$5.51

AFT Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 24, 2022

AFT Pharmaceuticals Limited Update on Maxigesic IV Us Registration Filing

AFT Pharmaceuticals Limited Completes Pascomer Clinical Study

Dr. Doug Wilson to Step Down from AFT Pharmaceuticals Board

US FDA Seeks More Information on AFT Pharmaceuticals Limited's Maxigesic IV Application

Price target decreased to NZ$4.40

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 05, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?

Investor sentiment improved over the past week

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year to 31 March 2023

AFT Pharmaceuticals Limited to Report Fiscal Year 2022 Results on May 23, 2022

Price target increased to NZ$5.88

AFT Pharmaceuticals Announces US Food and Drug Administration Approve Topical Treatment Indicated for Facial Angiofibroma

Independent Director recently bought NZ$66k worth of stock

Independent Director recently bought NZ$171k worth of stock

AFT Pharmaceuticals Limited Welcomes Australian Federal Court Appeal Success

Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?

First half 2022 earnings released: EPS NZ$0.04 (vs NZ$0.01 in 1H 2021)

Price target increased to NZ$5.88

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

AFT Pharmaceuticals Got First Regulatory Approval of Maxigesic Oral Liquid in Europe

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Full year 2021 earnings released

AFT Pharmaceuticals Limited Announces Earnings Guidance for the Fiscal Year 2022

CFO & Company Secretary exercised options to buy NZ$205k worth of stock.

Consensus EPS estimates fall to NZ$0.092

Price target decreased to NZ$4.95

AFT Pharmaceuticals Revises Earnings Guidance for the Year to 31 March 2021

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

AFT Pharmaceuticals Signs an Exclusive Maxigesic IV Licensing Agreement for Eight New European Markets

New 90-day low: NZ$4.21

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

New 90-day high: NZ$5.51

AFT Pharmaceuticals Limited Appoints Anita Baldauf as Non-Executive Director

New 90-day low: NZ$4.55

Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

Analysts lower EPS estimates to NZ$0.11

AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Revenue and earnings miss expectations

AFT Pharmaceuticals Limited Appoints Eddie Townslie as the Local Director of AFT Pharmaceuticals Europe

New 90-day high: NZ$5.46

AFT Pharmaceuticals Receives a US Food and Drug Administration Complete Response Letter Covering Its Application for the Approval of A Tablet Version of Its Maxigesic® Pain Relief Medication

AFT Pharmaceuticals Limited and Setek Sign Supply Agreement

AFT Pharmaceuticals Limited Appoints Anita Baldauf as a Non-Executive Director

AFT Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 19, 2020

New 90-day high - NZ$4.75

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz